1. Achieve sustained virologic response (SVR) in patients infected with HCV genotype 1, cirrhosis, and early clinical decompensation using 12 weeks of Olysio/Sovaldi/Ribavirin (or known as: Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin (RBV). 2. Hepatic improvement during and after Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) treatment using a new test of liver function, HepQuant-SHUNT.
Name: Simeprivir (SMV)
Description: Experimental Single arm study. All participants will get the same treatment.Type: DrugHCV positive group
Name: Sofosbuvir (SOF)
Description: Experimental Single arm study. All participants will get the same treatment.Type: DrugHCV positive group
Name: Ribavirin (RBV)
Description: Experimental Single arm study. All participants will get the same treatment.Type: DrugHCV positive group
Single Group Assignment
There is one SNP
Inclusion Criteria: 1. HCV genotype 1 infection (all subtypes and Q80K a type of mutation are allowed), and have been approved by a third party payer for the FDA-approved combination of sofosbuvir (SOF) plus ribavirin. --- Q80K ---